VP Program Management

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Tg Therapeutics Insider Sold Shares Worth $672,268, According to a Recent SEC Filing

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Manager, Patient Support

TG Therapeutics is a fully-integrated, commercial-stage biopharmaceutical company focused on developing treatments for B-cell diseases. The Manager, Patient Support will oversee the BRIUMVI Commercial Co-Pay Program and Free Goods Program, ensuring compliance and high-quality customer service for patients and healthcare providers.

Sign up with Google

Sign in with Google